Table 2. Different features of NMO and High risk patients according to their AQP4 Ab status.
| M1-M23- | M1-M23+ | M1+M23+ | p-value | |
| Number | 10 | 15 | 31 | |
| Females | 2 (20%) | 14 (93%) * | 29 (94%) * | <0.001 2 |
| Age (y) 1 | 40 (26–65) | 54 (18–77) | 49 (19–80) | 0.095 3 |
| Duration (m) 1 | 8 (0.8–60) | 45 (0.1–114) | 70 (0.4–540) *# | 0.009 3 |
| NMO | 1 (10%) | 8 (53%) | 21 (68%) * | 0.006 2 |
| Myelitis | 9 (90%) | 15 (100%) | 30 (97%) | 0.413 2 |
| LETM | 9 (90%) | 15 (100%) | 29 (94%) | 0.179 2 |
| ON | 2 (20%) | 8 (53%) | 22 (71%) * | 0.026 2 |
| Cerebral MRI | 0 (0%) | 5 (33%) | 8 (26%) | 0.131 2 |
| OCBs | 2 (20%) 5 | 2 (13%) 6 | 2 (7%) 7 | 0.675 2 |
| Relapses 1 | 1 (0–4) | 4 (1–13) * | 6 (1–15) * | <0.001 3 |
| M-23 IgG Titer 1 | - | 640 (40–10,240) | 2,560 (160–20,480) # | <0.001 4 |
| M-1 IgG Titer 1 | - | - | 160 (20–5,120) |
1
data are shown as median (range), p-value: groups were compared using 2 Chi-Square test and 3 Kruskal-Wallis test and Dunn's multiple comparison post-hoc test, 4 Mann-Whitney U test * statistically different from M1-M23- group at p<0.01, # statistically different from M1-M23+ group at p<0.01. data available of 5 8, 6 13 and 7 23 patients.
Abbreviations: n = number of patients, y = years, m = months.